Lilly says Phase 3 TRIUMPH-2, TRIUMPH-3 studies of retatrutide met primary endpoints in obesity
- Retatrutide delivered up to 20.8% average weight loss with up to 1.6% A1C reduction at 80 weeks in adults with obesity or overweight and type 2 diabetes in TRIUMPH-2.
- In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to 22.6% on retatrutide at 80 weeks; MACE events occurred less often than expected, with a reported MACE-5 hazard ratio of 0.82 versus placebo.
- Lilly said the two studies complete the clinical package for global submissions in obesity, knee osteoarthritis pain, and obstructive sleep apnea.
- The company plans to submit a BLA for retatrutide to the FDA in Q1 2027.